All In Biotech

Drug Trial Radar · NCT05684705

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

A Single Center, Open-label Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 (rifabutin for Infusion) in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Sep 1, 2023

Primary completion

Oct 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
BioVersys AGIndustry
Sponsor type
Industry
Collaborators
CW-Research and Management GmbH
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Conditions

  • Bacterial Infections

Interventions

  • BV100Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess plasma concentration of rifabutin in healthy participantsTime frame: 5 Days
  2. To assess epithelial lining fluid concentration of rifabutin in healthy participantsTime frame: 5 days
  3. To assess concentration of rifabutin in alveolar macrophages of healthy participantsTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of Vienna

    Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.